Testosterone therapy decreases subcutaneous fat and adiponectin in aging men

L. Frederiksen, K. Højlund, D. M. Hougaard, Thomas Hammershaimb Mosbech, Rasmus Larsen, A. Flyvbjerg, J. Frystyk, K. Brixen, M. Andersen

    Research output: Contribution to journalJournal articleResearchpeer-review


    OBJECTIVE: Testosterone therapy increases lean body mass and decreases total fat mass in aging men with low normal testosterone levels. The major challenge is, however, to determine whether the metabolic consequences of testosterone therapy are overall positive. We have previously reported that 6-month testosterone therapy did not improve insulin sensitivity. We investigated the effect of testosterone therapy on regional body fat distribution and on the levels of the insulin-sensitizing adipokine, adiponectin, in aging men with low normal bioavailable testosterone levels. DESIGN: A randomized, double-blinded, placebo-controlled study on 6-month testosterone treatment (gel) in 38 men, aged 60–78 years, with bioavailable testosterone 94 cm. METHODS: Central fat mass (CFM) and lower extremity fat mass (LEFM) were measured by dual X-ray absorptiometry. Subcutaneous abdominal adipose tissue (SAT), visceral adipose tissue (VAT), and thigh subcutaneous fat area (TFA) were measured by magnetic resonance imaging. Adiponectin levels were measured using an in-house immunofluorometric assay. Coefficients (b) represent the placebo-controlled mean effect of intervention. RESULTS: LEFM was decreased (b=–0.47 kg, P=0.07) while CFM did not change significantly (b=–0.66 kg, P=0.10) during testosterone therapy. SAT (b=–3.0%, P=0.018) and TFA (b=–3.0%, P
    Original languageEnglish
    JournalEuropean Journal of Endocrinology
    Issue number3
    Pages (from-to)469-476
    Publication statusPublished - 2012


    Dive into the research topics of 'Testosterone therapy decreases subcutaneous fat and adiponectin in aging men'. Together they form a unique fingerprint.

    Cite this